Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Horizon Licenses CRISPR Gene Editing Technology from Broad Institute

By Drug Discovery Trends Editor | June 13, 2014

Horizon Discovery Group plc announced it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system. 
 
Under the terms of the agreement, Horizon has rights to use the technology commercially for applications including development of research tools and reagents, and provision of services that utilize CRISPR, for example as part of Horizon’s GENASSIST offering. GENASSIST is a comprehensive product and service solution for CRISPR and rAAV gene editing, including guide RNA design and validation, donor design and a wide range of off-the-shelf plasmids.
 
The acquisition of additional CRISPR IP is in line with the Company’s aims outlined at the time of its IPO and further strengthens Horizon’s position in the market for this cutting edge gene editing technology. Access to a broader CRISPR IP portfolio will allow the technology to be deployed extensively across Horizon’s products, services and leveraged R&D and enhance the attractiveness of the Horizon GENESIS offering to customers.
 
The Broad Institute patent represents the first granted patent for use of CRISPR technology in eukaryotic cells and is based on work by Dr. Feng Zhang in a paper published in Science in 2013. More recently Dr. Zhang has published compelling results indicating CRISPR/Cas9-mediated gene editing can be employed in high-throughput genome-wide screens. This technology has the potential to revolutionize functional genomics and will also be offered as a service by Horizon.
 
“Horizon is committed to gaining access to the widest range of CRISPR IP possible.  We have taken this approach to ensure that our customers and partners are secure in the knowledge that they have the freedom to pursue their research and commercial goals when they choose to work with us. Building upon the Charpentier IP, in-licensed in early May, the Broad patent represents another important part of this program, and we are very pleased to be able to announce its addition to our growing portfolio of CRISPR licenses,” said Dr. Darrin Disley, CEO, Horizon Discovery Group plc. 
 
“Cas9 is revolutionizing many areas of biological research,” said Dr. Zhang, a core member of the Broad Institute and a pioneer of the CRISPR technology. “This technology has a lot of potential and we are excited to work with partners like Horizon to help put these powerful genome editing tools into the hands of researchers.”
 
Date: June 12, 2014
Source: Horizon Discovery
 

Filed Under: Drug Discovery

 

Related Articles Read More >

Ball-and-stick model of the cancer drug imatinib
After six years in stealth, Humanitas bets on hybrid AI for drug discovery
NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE